Pharma BD Deal Intelligence
Global generics empire expanded but contributed to serial acquisition debt burden
Full analysis, sources & comparables →Teva acquired Ivax for $7.4B, US rival generic drug manufacturer.
FTC requires divestitures before allowing Teva's $7.4 billion acquisition of IVAX, preserving competition by requiring the sale of rights to 15 generic…
Teva's $7.4 billion IVAX acquisition establishes the Israeli company as the world's dominant generic pharmaceutical manufacturer, transforming the competitive…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Teva Pharmaceutical Industries acquired IVAX Corporation for approximately $7.4 billion in a cash-and-stock transaction ($26 cash or 0.8471 Teva ADRs per share, subject to 50/50 proration), consolidating Teva's position as the world's largest generics company with combined revenues over $7 billion and strengthening its US and Latin American presence.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation (this deal) | 2005 | $7.4B | 62 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Barr Pharmaceuticals | 2008 | $7.5B | 58 |
← Browse all deals · How we score deals
More: 2005 deals · Teva Pharmaceutical Industries Ltd. deals · Neurology deals